2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 140.991 | 140.789 | 197.921 | 265.329 | 266.764 | 278.283 | 372.387 | 415.374 | 493.625 | 573.970 |
Total Income - EUR | 152.618 | 149.473 | 206.182 | 278.556 | 279.730 | 296.575 | 410.272 | 452.379 | 544.155 | 612.913 |
Total Expenses - EUR | 141.227 | 140.542 | 188.350 | 252.511 | 243.767 | 277.079 | 362.300 | 409.544 | 503.115 | 548.203 |
Gross Profit/Loss - EUR | 11.391 | 8.931 | 17.832 | 26.045 | 35.962 | 19.497 | 47.972 | 42.835 | 41.040 | 64.710 |
Net Profit/Loss - EUR | 9.536 | 7.474 | 15.319 | 22.885 | 33.168 | 16.636 | 44.425 | 39.455 | 36.820 | 59.135 |
Employees | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 4 |
Check the financial reports for the company - Omnapharm Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 22.037 | 21.701 | 26.312 | 23.597 | 21.108 | 38.517 | 36.160 | 40.831 | 40.571 | 44.072 |
Current Assets | 43.890 | 54.155 | 75.453 | 89.478 | 101.391 | 100.011 | 142.528 | 163.737 | 163.491 | 196.425 |
Inventories | 20.365 | 26.840 | 40.452 | 44.457 | 52.085 | 50.211 | 82.451 | 90.006 | 85.452 | 118.656 |
Receivables | 20.457 | 17.602 | 13.254 | 33.703 | 41.086 | 38.153 | 54.984 | 60.405 | 69.897 | 68.393 |
Cash | 3.068 | 9.713 | 21.748 | 11.318 | 8.220 | 11.647 | 5.093 | 13.326 | 8.142 | 9.375 |
Shareholders Funds | 36.232 | 38.744 | 28.791 | 52.084 | 62.806 | 57.345 | 80.009 | 97.474 | 110.263 | 142.783 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 29.695 | 37.112 | 72.975 | 60.991 | 59.693 | 82.172 | 99.238 | 107.339 | 93.799 | 97.714 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Omnapharm Srl